Pathogenetic Therapy in Patients with Recurrent Herpetic Infection

Abstract

When treating patients with recurrent herpesvirus infection, it is necessary to use combination therapy, which involves the use of both chemotherapy and immunotropic drugs. Simultaneous use of drugs with different mechanisms of action allows to achieve greater efficiency than the use of monotherapy. The effectiveness of Cycloferon, an interferon inducer, which has an anti-inflammatory and immunomodulatory effect in combination therapy in patients with labial herpes, has been established. An accelerated elevation of rashes was observed against the background of the use of Cycloferon in combination therapy with acyclic nucleosides (Acyclovir); the severity of general intoxication syndrome, subjective symptoms (pain, itching, burning), and signs of inflammation (edema, hyperemia) decreased by half compared with the control group. Also, an increase in the duration of remission by 2–2.5 times was observed in patients taking Cycloferon. High efficiency, good tolerance by patients, as well as the possibility of using it with the main antiviral chemotherapy drugs indicate the advisability of including Cycloferon in the combination therapy in patients with recurrent herpes infection.